Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Formulations of Ixekizumab in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are healthy male or female participants, with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study~Exclusion Criteria:~* Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study~* Are allergic or hypersensitive to the study medicine~* Had a vaccination with a live vaccine within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study~* Have any type of hepatitis, human immunodeficiency virus (HIV) infection, or other serious infection~* Show evidence of active or latent tuberculosis (TB)~* Presence of significant neuropsychiatric disorder or a recent history of depression~* Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator, would pose an unacceptable risk to the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Ixekizumab (Reference) (Type: EXPERIMENTAL): Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
- Ixekizumab (Test) (Type: EXPERIMENTAL): Test formulation of 80 mg ixekizumab administered as a SC injection via AI.

Based on this trial design, predict the completion outcome and termination type (if applicable).